Viking expects oral VK2735 Phase III start in fourth quarter as VANQUISH targets 78-week dosing

Phase 3VK2735Positive

AI Analysis

Summary

Viking Therapeutics expects to initiate a Phase III trial of oral VK2735 in the fourth quarter of 2026, with the VANQUISH study targeting a 78-week dosing regimen.

Clinical Trial Data

Phase

Phase 3

Importance:7/10

Sentiment:

0.50

Phase 3VK2735oral formulationVANQUISHViking Therapeutics

Related Companies

$VKTX

Read the original article

Published by Seeking Alpha Healthcare on July 30, 2026 2:56 AM

Read Original